Sientra Closes $65M Series C Financing

Sientra, a Santa Barbara, CA-based medical device company focused on the aesthetic and plastic surgery markets, has closed a $65m Series C financing

The round was led by Abingworth, with participation by Clarus Ventures, OrbiMed Advisors and all other insiders.
This investment brings the total equity capital raised by the company to $151m.

Sientra intends to use the capital to commercialize its recently FDA-approved portfolio of Silicone Breast Implants, as well as fund general operations and provide working capital.

Founded in 2007 by CEO Hani Zeini, the company focuses on the aesthetics and plastic surgery market. 
On March 9, 2012, the United States Food and Drug Administration (FDA) approved its application for premarket approval (PMA) of its entire portfolio of Silimed®-brand silicone gel breast implants including its shaped implants and classical round implants product lines. 
Sientra’s products also include an extensive array of 510(k) products focused on reconstructive surgery and body contouring. 



One comment

  • I don’t know if the approval of this implant is a good or bad news for the market. In the middle of PIP breast implant crisis, is it really a good timing to release this approval? I mean, the issue of PIP implants is not yet settled. Although, US is not covered by this news, still the silicone implants industry is in the hot seat. Questions like, is it really safe, how patients can determine the assure its legit are few of the upcoming issues plastic surgeons should answer.

Join the discussion